Pyxis Oncology, Inc. PYXS
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Pyxis Oncology, Inc. (PYXS) is a healthcare company listed in the US with a market value of about $189M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$87M, a net margin of -785.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -55%.
About Pyxis Oncology
Pyxis Oncology is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 88% over three years (dilution for shareholders). It spends 532% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $11M | $14M | $16M | — | — | — | — |
| Net income | -$87M | -$80M | -$77M | -$74M | -$121M | -$76M | -$13M |
| Free cash flow | -$71M | -$64M | -$58M | -$77M | -$96M | -$36M | -$12M |
| EPS (diluted) | $-1.27 | $-0.64 | $-0.66 | $-0.93 | $-1.82 | $-4.47 | $-6.22 |
| Net margin | -785.5% | -574.5% | -479.0% | — | — | — | — |
| ROIC | — | -92.5% | -61.8% | -44.2% | -54.3% | -21.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $8.22, 420% above the current price; targets range from $5.00 to $19.00; the consensus rating is “Strong buy”; expected EPS is $-1.08 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Pyxis Oncology pay a dividend?
Not currently.
Is Pyxis Oncology a good stock to buy?
We do not give buy or sell advice. Pyxis Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.